- Home
- ATEX vs LYEL Comparison
ATEX vs LYEL Comparison
Compare ATEX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEX | LYEL |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.4M | 490.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATEX | LYEL |
|---|---|---|
| Price | $36.85 | $24.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $50.00 | $25.00 |
| AVG Volume (30 Days) | ★ 509.8K | 94.8K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $6,031,000.00 | $61,000.00 |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | $4.32 | N/A |
| P/E Ratio | $9.39 | ★ N/A |
| Revenue Growth | ★ 43.90 | N/A |
| 52 Week Low | $17.58 | $0.39 |
| 52 Week High | $39.62 | $45.00 |
Technical Indicators
Market Signals| Indicator | ATEX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 71.93 | 50.85 |
| Support Level | $20.12 | $21.27 |
| Resistance Level | N/A | $27.30 |
| Average True Range (ATR) | 2.41 | 2.49 |
| MACD | 0.39 | 0.10 |
| Stochastic Oscillator | 86.36 | 58.07 |
Price Performance
Historical ComparisonAbout ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.